Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 9, 2004, Pages 1004-1022

  Dunphy, Cherie H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN DETECTION; B CELL LEUKEMIA; B CELL LYMPHOMA; CELL STRUCTURE; CYTOGENETICS; DIAGNOSTIC TEST; FLOW CYTOMETRY; FOLLOW UP; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PLASMA CELL DYSCRASIA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; THYMOMA;

FLOW CYTOMETRY; HEMATOLOGIC DISEASES; HEMATOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOMA;

EID: 4444316754     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Dunphy CH, Dunphy FR, Visconti JL. Flow cytometric immunophenotyping of bone marrow core biopsies: report of 8 patients with previously undiagnosed hematologic malignancy and failed bone marrow aspiration. Arch Pathol Lab Med. 1999;123:206-212.
2. Dunphy CH, Ramos R. Combining fine-needle aspiration and flow cytometric immunophenotyping in evaluation of nodal and extranodal sties for possible lymphoma: a retrospective review. Diagn Cytopathol. 1997;16:200-206.
3. Dunphy CH. Combined cytomorphologic and immunophenotypic approach to evaluation of effusions for lymphomatous involvement. Diagn Cytopathol. 1996;15:427-430.
4. Weisberger J, Cornfield D, Gorczyca W, Liu Z. Down-regulation of pan-T-cell antigens, particularly CD7, in acute infectious mononucleosis. Am J Clin Pathol. 2003;120:49-55.
5. Moll M, Reinhold U, Kukel S, et al. CD7-negative helper T cells accumulate in inflammatory skin lesions. J Invest Dermatol. 1994;102:328-332.
6. +patients. Am J Dermatopathol. 1995;17:564-569.
7. - T cells in rheumatoid arthritis. Arthritis Rheum. 1992;35:615-624.
8. Dunphy CH. Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma? Cytometry. 2000;42:296-306.
9. Gong JZ, Williams DC Jr, Liu K, Jones C. Fine-needle aspiration in non-Hodgkin lymphoma: evaluation of cell size by cytomorphology and flow cytometry. Am J Clin Pathol. 2002;117:880-888.
10. Chen X, Jensen PE, Li S. HLA-DO: a useful marker to distinguish florid follicular hyperplasia from follicular lymphoma by flow cytometry. Am J Clin Pathol. 2003;119:842-851.
11. Cook JR, Craig FE, Swerdlow SH. Bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow. Am J Clin Pathol. 2003;119:145-151.
12. Li S, Eshleman JR, Borowitz MJ. Lack of surface immunoglobulin light chain expression by flow cytometric immunphenotyping can help diagnose peripheral B-cell lymphoma. Am J Clin Pathol. 2002;118:229-234.
13. Gupta D, Lim MS, Medeiros LJ, Elenitoba-Johnson KSJ. Small lymphocytic lymphoma with perifollicular, marginal zone, or interfollicular distribution. Mod Pathol. 2000;13:1161-1166.
14. Gong JZ, Lagoo AS, Peters D, et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116:893-897.
15. McCarron KF, Hammel JP, Hsi ED. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders. Am J Clin Pathol. 2000;113:805-813.
16. Schlette E, Medeíros LJ, Keating M, Lai R. CD79b expression in chronic lymphocytic leukemia: association with trisomy 12 and atypical immunophenotype. Arch Pathol Lab Med. 2003;127:561-566.
17. - mantle cell lymphoma. Am J Clin Pathol. 2002;118:216-224.
18. Frater JL, McCarron KF, Hammel JP, et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol. 2001;116:655-664.
19. Zaer FS, Braylan RC, Zander DS, Iturraspe MT, Almasri NM. Multiparametric flow cytometry in the diagnosis and characterization of low-grade pulmonary mucosa-associated lymphoid tissue lymphomas. Mod Pathol. 1998;11:525-532.
20. + extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31-37.
21. - small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia. Am J Clin Pathol. 1999;111:123-130.
22. Dunphy CH, Lattuada LP Jr. Follicular center cell lymphoma with an extremely high content of T cells: case report with useful diagnostic techniques. Arch Pathol Lab Med. 1998;122:936-938.
23. Dunphy CH, Wolaniuk JW, Turgeon RP. Flow cytometric findings in the floral variant of follicular lymphoma. J Clin Lab Anal. 1998;12:310-314.
24. Sandhaus LM, Voelkerding K, Raska K. Follicular lymphoma mimicking transformation of germinal centers: immunologic analysis of a case. Am J Clin Pathol. 1988;90:518-519.
25. + follicle center lymphoma: immunophenotyping dectects a unique subset of "floral" follicular lymphoma. Am J Clin Pathol. 2000;114:912-921.
26. Dunphy CH, Oza YU, Skelly ME. An otherwise typical case of non-Japanese hairy cell leukemia with CD10 and CDw75 expression: response to cladaribine phosphate therapy. J Clin Lab Anal. 1999;13:141-144.
27. + hairy cell leukemia. Am J Clin Pathol. 2003;120:228-235.
28. Kampalath B, Barcos MP, Stewart C. Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2003;1993:824-832.
29. Ibrahim S, Keating M, Kim-Anh D, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181-186.
30. Del Poeta C, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98:2633-2639.
31. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1767-1775.
32. Weistner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
33. McKenna RW, Washington LT, Aquino DB, et al. lmmunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498-2507.
34. Keren DF, Hanson CA, Hurtubise PE, eds. Flow Cytometry and Clinical Diagnosis. Chicago, III: ASCP Press; 1994:214.
35. Nakajima J, Takamoto S, Oka T, Tanaka M, Takeuchi E, Murakawa T. Flow cytometric analysis of lymphoid cells in thymic epithelial neoplasms. Eur J Cardiothorac Surg. 2000;18:287-292.
36. Cessna MH, Dunphy C, Brown M, et al. Differentiation of thymoma from T-lymphoblastic lymphoma by flow cytometry. Mod Pathol. 2002;15:234A(981).
37. Ortonne N, Buyukbabani N, Delfau-Larue M-H, Bagot M, Wechsler J. Value of the CD8-CD3 ratio for the diagnosis of mycosis fungoides. Mod Pathol. 2003;16:857-862.
38. Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-633.
39. Attygalle A, Diss TC, Isaacson PG, Dogan A. CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma [abstract]. Mod Pathol. 2002:964.
40. + memory T cells [abstract]? Mod Pathol. 2002:1125.
41. Cook JR, Craig FE, Swerdlow SH. Benign CD10-positiveT cells in reactive lymphoid proliferations and B-cell lymphomas. Mod Pathol. 2003;16:879-885.
42. β antibodies. Am J Clin Pathol. 2003;120:785-794.
43. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89:256-260.
44. Zambello R, Trentin L, Ciccone E, et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood. 1993;81:2381-2385.
45. Dunphy CH, Gardner LJ, Grosso LE, et al. Flow cytometric immunophenotyping in posttransplant lymphoproliferative disorders. Am J Clin Pathol. 2002;117:24-28.
46. Grogan TM, Durie BC, Spier CM, Richter L, Vela E. Myelomonocytic antigen positive multiple myeloma. Blood. 1989;73:763-769.
47. Durie BGM, Grogan TM. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood. 1985;66:229-232.
48. Newell JO, Cessna MH, Greenwood J, Hartung L, Bahler DW. Importance of CD117 in the evaluation of acute leukemias by flow cytometry. Clin Cytometry. 2003;52B:40-43.
49. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosome abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470-477.
50. Brandt JT, Tisone JA, Bohman JE, Thiel KS. Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia. Am J Clin Pathol. 1997;107:283-291.
51. Krasinska AM, Wasik MA, Kamoun M, Scrhetzenmair R, Moore J, Salhany KE. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol. 1998;110:797-805.
52. Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med. 2003;127:1140-1147.
53. Dunphy CH, Orton SM, Mantell JL. Comparison of flow cytometric immunophentypic (FCI) findings in acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), and normal monocytes. Mod Pathol. 2004. In press.
54. Struchen JA, Miller LK. Lymph node infarction: an immunohistochemical study of 11 cases. Arch Pathol Lab Med. 2003;127:60-63.
55. Norton AJ, Ramsay AD, Isaacson PG. Antigen preservation in infracted lymphoid tissue. A novel approach to the infracted lymph node using monoclonal antibodies effective in routinely processed tissues. Am J Surg Pathol. 1988;12:759-767.
56. Browne G, Tobin B, Carney DN, Dervan PA. Aberrant MT2 positivity distinguishes follicular lymphoma from reactive follicular hyperplasia in B5- and formalin-fixed paraffin sections. Am J Clin Pathol. 1991;96:90-94.
57. Ngan B-Y, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomeal translocation. N Engl J Med. 1998;318:638-644.
58. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology. 1995;26:89-93.
59. Meda BA, Frost M, Newell J, et al. Bcl-2 is consistently expressed in hyperplastic marginal zones of the spleen, abdominal lymph nodes, ileal lymphoid tissue. Am J Surg Pathol. 2003;27:888-894.
60. Skinnider BF, Horsman DE, Dupuis B, Cascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Human Pathol. 1999;30:803-808.
61. Pezzella F, Tse GD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990;137:225-232.
62. Wheaton S, Netser J, Guinee D, Rahn M, Perkins S. Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-Hodgkin's lymphomas. Hum Pathol. 1998;29:820-825.
63. Lai R, Arber DA, Chang KL, Wilson CS, Weiss LM. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol. 1998;11:864-869.
64. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346-1356.
65. Torlakovic E, Torlakovic G, Nguyen PL, Burnning RD, Delabie J. The value of anti-Pax-5 immunostaining in routinely fixed and paraffin-embedded sections. A novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-1350.
66. Butmarc JR, Kourea HP, Levi E, Kadin ME. Improved detection of CD5 epitope in formalin-fixed paraffin-embedded sections of benign and neoplastic lymphoid tissues by using biotinylated tyramine enhancement after antigen retrieval. Am J Clin Pathol. 1998;109:682-688.
67. Ito M, Iida S, Inagaki H, et al. MUM1/IRF4 expression is an unfavorable prognostic marker in B-cell chronic lymphocytic leukemia (CLL/small lymphocytic lymphoma (SLL). Jpn J Cancer Res. 2002;93:685-694.
68. Tsuboi K, Inagaki H, Kalo M. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia. 2000;14:449-456.
69. Carbone A, Gloghini A, Aldinucci D, Cartel V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol. 2002;117:336-372.
70. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084-2092.
71. Belaud-Rotureau M-A, Parrens M, Dubus P, et al. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol. 2002;15:517-525.
72. Miranda RN, Briggs RC, Kinney MC, Veno PA, Hammer RD, Cousar JB. lmmunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Mod Pathol. 2000;13:1308-1314.
73. Zukerberg LR, Yang W-I, Arnold A, Harris NL. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol. 1995;103:756-760.
74. Hounieu M, Chittal SM, al Saati T. Hairy cell leukemia: diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol. 1992;98:26-33.
75. Gramatzki M, Burger R, Kraus J, et al. Monoclonal antibodies EBU-141 (CDw75) and EBU-65 allow reliable distinction between mature and pre-B-cell tumors in suspension and on tissue sections. Ann Hematol. 1991;63:20-26.
76. Ree HJ, Kadin ME, Kikuchi M, Ko YH, Suzumiya J, Go JH. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma. Hum Pathol. 1999;30:403-411.
77. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol. 1999;112:101-107.
78. Ree HJ, Yang WI, Kim CW, et al. Coexpression of bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Hum Pathol. 2001;32:954-962.
79. Dunphy CH, Polski JM, Evans HL, Gardner LJ. Paraffin immunoreactivity of CD10, CDw75, and Bcl-6 I follicle center cell lymphoma. Leuk Lymphoma. 2001;41:585-592.
80. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94:318-323.
81. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101:78-84.
82. - diffuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol. 2001;116:183-190.
83. Chang C-C, Cleveland RP, Perkins SL. CD10 expression and survival. Am J Clin Pathol. 2002;117:660-661.
84. Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; Sept. 22 (Epub). Available at www. bloodjournal.org.
85. Nakamura N, Nakamine H, Tamaru J-I, et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771-776.
86. Kwon MS, Co JH, Choi JS, et al. Critical evaluation of bcl-6 protein expression in diffuse large B-cell lymphoma of the stomach and small intestine. Am J Surg Pathol. 2003;27:790-798.
87. Chang C-C, Kampalath B, Schultz C, et al. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med. 2003;127:208-212.
88. Chang C, Liu Y, Cleveland RP, Perkins SL. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol. 2000;113:512-518.
89. Braaten KM, Betensky RA, de Levai L. Bcl-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9:1063-1069.
90. Yamaguchi M, Ohno T, Oka K. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999;105:1133-1139.
91. + diffuse large B-cell lymphomas. A heterogenous group containing an unusual form of splenic lymphoma. Am J Clin Pathol. 2000;114:523-533.
92. + Burkitt lymphoma/leukemia. Am J Clin Pathol. 1999;112:828-835.
93. de Levai L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B-cells. Am J Surg Pathol. 2001;25:1277-1282.
94. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15:1172-1180.
95. Pileri SA, Caidano C, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of bcl-6 mutations and consistent expression of the transcription factors Oct-2, BOB.1, and Pu.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243-253.
96. McBride JA, Rodriguez J, Luthra R, et al. T-cell-rich B-cell lymphoma simulating lymphocyte-rich Hodgkin disease. Am J Surg Pathol. 1996;20:193-201.
97. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin disease and related disease ('gray zone' lymphoma). Ann Oncol. 1998;9:31-38.
98. Schmidt U, Metz KA, Leder LD, et al. T-cell-rich B-cell lymphoma and lymphocyte predominant Hodgkin disease: two closely related entities? Br J Haematol. 1990;2:398-403.
99. + anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol. 2001;12:853-858.
100. + patients: an expanding spectrum. Histopathology. 2003;42:605-609.
101. Adam P, Katzenberger T, Seeberger H, et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol. 2003;27:1473-1476.
102. - large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol. 2003;16:828-832.
103. Carbone A, Goghini A, Cozzi MR, et al. Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. Br J Haematol. 2000;111:247-257.
104. Polski JM, Evans HL, Grosso LE, Popovic WJ, Taylor L, Dunphy CH. CD7 and CD56-positive primary effusion lymphoma in a human immunodeficiency virus-negative host. Leuk Lymphoma. 2000;39:633-639.
105. Carbone A, Gloghini A, Volpe R, Pinto A. KP1 (CD68)-positive large cell lymphomas: a histopathologic and immunophenotypic characterization of 12 cases. Hum Pathol. 1993;24:886-896.
106. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398-404.
107. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002;118:773-779.
108. Saffer H, Warhed A, Rassidakis GZ, Medeiros J. Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod Pathol. 2002;15:1221-1226.
109. Liang X, Golitz LE, Smoller BR, et al. Association of expression of CD44v6 with systemic anaplastic large Cell lymphoma: comparison with primary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002;117:276-282.
110. Segal GH, Kjeldsberg CR, Smith GP, Perkins SL. CD30 antigen expression in florid immunoblastic proliferations: a clinicopathologic study of 14 cases. Am J Clin Pathol. 1994;102:292-298.
111. Cohen PL, Butmarc J, Kadin ME. Expression of Hodgkin's disease associated antigen BLA.36 in anaplastic large cell lymphomas and lymphomatoid papulosis primarily of T-cell origin. Am J Clin Pathol. 1995;104:50-53.
112. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 2001;25:1364-1371.
113. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KSJ, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569-576.
114. Zukerberg LR, Collins AB, Ferry JA, et al. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol. 1991;139:475-483.
115. Warnke RA, Weiss LM, Chan JKC, et al. Tumors of the Lymph Nodes and Spleen. Washington DC: Armed Forces Institute of pathology; 1995. Atlas of Tumor Pathology; fascicle 14.
116. Schmid C, Pan L, Dis T, et al. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139:701-707.
117. Korkopoulou P, Cordell J, Jones M, et al. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease. Histopathology. 1994;24:511-515.
118. Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classical Hodgkin lymphoma. Am J Clin Pathol. 2003;120:767-777.
119. Arber DA, Weiss LM. CD15: a review. Appl Immunohistochem. 1993;1:17-30.
120. Delsol C, Al Sasti T, Carter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphoma. Am J Pathol. 1988;130:59-70.
121. Chott A, Kaserer K, Augustin I, et al. Ki-1-positive large cell lymphoma: a clinicopathologic study of 41 cases. Am J Surg Pathol. 1990;14:439-448.
122. Greer JP, Kinney MC, Collins RD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol. 1991;9:539-547.
123. Fan C, Kotylo P, Neiman RS, Braziel RM. Comparison of fascion expression in anaplastic large cell lymphoma and Hodgkin disease. Am J Clin Pathol. 2003;119:199-204.
124. Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27:1513-1522.
125. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol. 1998;29:397-403.
126. Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol. 1997;150:1893-1900.
127. Harris NL, Ferry JA, Swerdlow SH. Post-transplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin. Diagn Pathol. 1997;14:8-14.
128. Horny H-P, Wehrmann M, Steinke B, Kaiserling E. Assessment of the value of immunohistochemistry in the subtyping of acute leukemia on routinely processed bone marrow biopsy sepecimens with particular reference to macrophage-associated antibodies. Hum Pathol. 1994;25:810-814.
129. Arber DA, Jenkins KA. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. Am J Clin Pathol. 1996;106:462-468.
130. Chuang S-S, Li C-Y. Useful panel of antibodies for the classification of acute leukemia by immunohistochemical methods in bone marrow trephine biopsy specimens. Am J Clin Pathol. 1997;107:410-418.
131. Chang CC, Eshoa C, Kampalath B, Shidham VB, Perkins S. Imunophenotypic profile of myeioid cells in granulocytic sarcoma by immunohistochemistry: correlation with blast differentiation in bone marrow. Am J Clin Pathol. 2000;114:807-811.
132. Horny H-P, Campbell M, Steinke B, Kaiserling E. Acute myeioid leukemia: immunohistologic findings in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1990;21:648-655.
133. Manaloor EJ, Neiman RS, Heilman DK, et al. Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens: comparison with flow cytometry. Am J Clin Pathol. 2000;113:814-822.
134. Dunphy CH, Polski JM, Evans L, Gardner LJ. Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117 and myeloperoxidase: comparison of flow cytometric and enzyme cytochemical versus immunohistochemical techniques. Arch Pathol Lab Med. 2001;125:1063-1069.
135. Ghannadan M, Wimazal F, Simonitsch I, et al. Immuohistochemical detection of VEGF in the bone marrow of patients with acute myeioid leukemia: correlation between VEGF expression and the FAB category. Am J Clin Pathol. 2003;119:663-671.
136. Soslow RA, Bhargava V, Warnke RA. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Hum Pathol. 1997;28:1158-1165.
137. Orazi A, Cattoretti G, John K, Neiman RS. Terminal deoxynuclotidyl transferase staining of malignant lymphomas in paraffin sections. Mod Pathol. 1994;7:582-586.
138. Kang LC, Dunphy CH. Immunoreactivity of MIC2 and terminal deoxytransferase (TdT) in bone marrow (BM) clot and core specimens of acute myeioid leukemia (AML) and myelodysplastic syndromes (MDS). Mod Pathol. 2004;17:254A (1069).
139. Costes V, Magen V, Legouffe E. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1999;30:1405-1411.
140. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999;12:1101-1106.
141. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002;100:661-665.
142. Horny H-P, Ruck P, Xiao J-C, Kaiserling E. Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1. Hum Pathol. 1993;24:355-358.
143. Horny H-P, Lange K, Sotlar K, Valent P. Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol. 2003;56:575-578.
144. Kip1 immunostaining for the differential diagnosis of small B-cell neoplasms in trephine bone marrow biopsies. Mod Pathol. 2001;14:1022-1029.
145. Bluth RF, Casey TT, McCurley TL. Differentiation of reactive from neoplastic small-cell lymphoid aggregates in paraffin-embedded marrow particle preparations using L-26 (CD20) and UCHL-1 (CD45RO) monoclonal antibodies. Am J Clin Pathol. 1993;99:150-156.
146. Ben-Ezra JM, King BE, Harris AC, Todd WM, Kornstein MJ. Staining for bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. Mod Pathol. 1994;7:560-564.